Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 10

Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

September 18, 2024

Hope Rugo, MD, Aditya Bardia, MD, MPH, FASCO

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Current ADCs in Breast Cancer

EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components

EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia

EP. 5: Navigating SG-related Diarrhea

EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd

EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

Now Viewing

EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP. 11: Future Perspectives on ADCs in Breast Cancer

EP. 12: Expert Insights: Investigational ADCs Safety Profiles

EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

lease describe the role of the multidisciplinary team in the management of treatment-resistant adverse effects for your patients who are receiving antibody-drug conjugates.